Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/13658
Title: Non-bacterial infections in Asian patients treated with alemtuzumab: A retrospective study of the Asian Lymphoma Study Group
Authors: Seok Jin Kim
Joon Ho Moon
Hawk Kim
Jin Seok Kim
Yu Yan Hwang
Tanin Intragumtornchai
Surapol Issaragrisil
Jae Yong Kwak
Je Jung Lee
Jong Ho Won
Arry Harryanto Reksodiputro
Soon Thye Lim
Ann Lii Cheng
Won Seog Kim
Yok Lam Kwong
SungKyunKwan University, School of Medicine
Kyungpook National University Hospital
University of Ulsan, College of Medicine
Yonsei University College of Medicine
Queen Mary Hospital Hong Kong
Chulalongkorn University
Mahidol University
Chonbuk National University, School of Medicine
Chonnam National University, College of Medicine
Soonchunhyang University, College of Medicine
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
National Cancer Centre, Singapore
National Taiwan University Hospital
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 1-Aug-2012
Citation: Leukemia and Lymphoma. Vol.53, No.8 (2012), 1515-1524
Abstract: This retrospective study concerns non-bacterial infections in Asian patients receiving alemtuzumab. The clinical data of 182 patients treated with alemtuzumab alone or alemtuzumab-containing chemotherapy between the years 2003 and 2009 was collected from six Asian countries. Alemtuzumab was used in the setting of frontline (n = 48) or salvage (n = 90) treatment, and as a part of the conditioning regimen for allogeneic stem cell transplant (n = 44). Reactivation of cytomegalovirus (66/182) and varicella zoster virus (25/182), and fungal infection (31/182) including invasive pulmonary aspergillosis, were the most common infectious complications in this retrospective analysis. Thus, we recommend routine prophylaxis with valganciclovir and itraconazole, especially when alemtuzumab is used in the conditioning regimen for allogeneic stem cell transplant. Pneumocystis jirovecii pneumonia (PJP) was found in four patients (3%, 4/122) receiving alemtuzumab as conditioning for stem cell transplant or salvage treatment. Three cases of hepatitis B virus reactivation were found in antigen-negative patients, and 16 cases of tuberculosis were observed. Infection is the major complication of alemtuzumab therapy, and these infectious complications are potentially severe and life-threatening. Based on our retrospective analysis, we have constructed a guideline for antimicrobial prophylaxis in Asian patients receiving alemtuzumab therapy. © 2012 Informa UK, Ltd.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84864245939&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/13658
ISSN: 10292403
10428194
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.